Is cancer gene therapy an empty suit?

Summary Gene therapy as a treatment for cancer is regarded as high in promise, but low in delivery, a deficiency that has become more obvious with ever-increasing reports of the successful correction of monogenic disorders by this approach. We review the commercial and scientific obstacles that have...

Full description

Saved in:
Bibliographic Details
Published in:The lancet oncology 2013-10, Vol.14 (11), p.e447-e456
Main Authors: Brenner, Malcolm K, Prof Dr, Gottschalk, Stephen, Prof, Leen, Ann M, PhD, Vera, Juan F, MD
Format: Article
Language:English
Subjects:
Animals
Biodistribution
Biological products
Cancer therapies
Disease
Gene therapy
Genes, Tumor Suppressor
Genetic disorders
Genetic engineering
Genetic Therapy
Hematology, Oncology and Palliative Medicine
Hemophilia
Humans
Immune system
Immunotherapy
Neoplasms - genetics
Neoplasms - therapy
Pharmaceutical industry
Success
Tumors
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Summary Gene therapy as a treatment for cancer is regarded as high in promise, but low in delivery, a deficiency that has become more obvious with ever-increasing reports of the successful correction of monogenic disorders by this approach. We review the commercial and scientific obstacles that have led to these delays and describe how they are progressively being overcome. Recent and striking successes and correspondingly increased commercial involvement suggest that gene transfer could finally become a powerful method for development of safe and effective cancer therapeutic drugs.
ISSN:1470-2045
1474-5488
DOI:10.1016/S1470-2045(13)70173-6